首页 | 本学科首页   官方微博 | 高级检索  
检索        

巯甲丙脯酸生物黏附型缓释胶囊大鼠体内药动学研究
引用本文:宋益民,范鸣浩,张丽,张学成.巯甲丙脯酸生物黏附型缓释胶囊大鼠体内药动学研究[J].中国药房,2010(13):1162-1164.
作者姓名:宋益民  范鸣浩  张丽  张学成
作者单位:青岛科技大学制药工程系;中国海洋大学生命学院;
基金项目:国家自然科学基金资助项目(30471317)
摘    要:目的:建立高效液相色谱-紫外检测器法检测大鼠灌胃巯甲丙脯酸生物黏附型缓释胶囊(CBSRCs)后巯甲丙脯酸(Cap)的血药浓度的方法,并进行药动学研究。方法:30只大鼠随机分组,分别单剂量灌胃CBSRCs和巯甲丙脯酸普通片(COT)各5mg·kg-1,高效液相色谱法测定各时间点血药浓度,DAS2.0药动学软件计算出相应的药动学参数,并用t检验比较数据。结果:Cap检测浓度线性范围为12.5~800μg·L-1(r=0.9987),最低检测限12.5μg·L-1,平均回收率为99.40%,RSD<8.60%。灌服CBSRCs和COT后tmax分别为(3.12±0.67)、(1.53±0.27)h,Cmax(722.97±133.68)、(1114.47±208.36)μg·L-1,t1/2α(1.88±0.38)、(1.15±0.21)h,t1/2β(3.76±0.75)、(2.87±0.59)h,CL(2.87±0.51)、(3.43±0.67)L·h-1,Vd(10.98±1.90)、(13.21±2.57)L,AUC0~t(4856.03±835.46)、(4616.29±915.49)μg·h·L-1,MRT(5.53±1.03)、(3.71±0.66)h,各参数两两比较均有显著性差异(P<0.05或<0.01)。结论:高效液相色谱-紫外检测器法测定Cap浓度的方法稳定,结果准确可靠;与普通制剂比较,CBSRCs具有缓释和长效性。

关 键 词:巯甲丙脯酸  缓释胶囊  大鼠  血药浓度  药动学  高效液相色谱-紫外检测器法

Pharmacokinetic Study of Captopril Bioadhesive Sustained-release Capsules in Rats
SONG Yi-min,FAN Ming-hao,ZHANG Li SONG Yi-min,ZHANG Xue-cheng.Pharmacokinetic Study of Captopril Bioadhesive Sustained-release Capsules in Rats[J].China Pharmacy,2010(13):1162-1164.
Authors:SONG Yi-min  FAN Ming-hao  ZHANG Li SONG Yi-min  ZHANG Xue-cheng
Institution:SONG Yi-min,FAN Ming-hao,ZHANG Li(Dept.of Pharmaceutical Engineering,Qingdao University of Science & Technology,Qingdao 266042,China) SONG Yi-min,ZHANG Xue-cheng(College of Life Science,Ocean University of China,Qingdao 266003,China)
Abstract:OBJECTIVE: To establish an HPLC-UVD method for the determination of plasma concentration of captopril (Cap) in rats administrated with Captopril bioadhesive sustained-release capsules (CBSRCs) via i.g and study its pharmacokinetics. METHODS: 30 rats were randomly given oral signal dose of 5 mg·kg^-1 CBSRCs or 5 mg·kg^-1 Captopril oral tablets (COT). The plasma concentration of Cap was measured by HPLC. The pharmacokinetics parameters of two preparations were calculated using DAS 2.0 software and compared in t-test. RESULTS: The linear range of Cap was 12.5-800 μg.L^-1(r=0.998 7) with an average recovery of 99.40% (RSD〈8.60%). Minimum detectable concentration was 12.5 μg·L^-1. Main pharmacokinetics parameters of CBSRCs vs. COT were as follows: tmax: (3.12 ± 0.67) VS. (1.53 ± 0.27 ) h; Cmax(722.97± 133.68) vs. (1 114.47 ± 208.36) μg·L^-1; t1-2 (1.88± 0.38) vs. (1.15 ±0.21 ) h; &2,(3.76± 0.75) vs. (2.87± 0.59) h; CL(2.87± 0.51) vs. (3.43± 0.67 )L. h^-1; Vd(10.98 ± 1.90) vs. (13.21 ± 2.57) L; AUC0-1(4 856.03±835.46) vs. (4 616.29 ± 915.49) μg.h.L^-1; MRT(5.53±1.03) vs. (3.71 ± 0.66) h. Significant difference was noted in pharmacokinetic parameters (P〈0.05 or P〈0.01 ). CONCLUSION: The HPLC-UVD method is accurate and reliable for the determination of plasma concentration of Cap. As compared with COT, CBSRCs shows sustained-release and long-term effect characteristic.
Keywords:Captopril  Sustained-release capsules  Rat  Plasma concentration  Pharmacokinetics  HPLC-UVD methods  
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号